Communiqués InnoCare Pharma Limited

Actions

9969

KYG4783B1032

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:42 28/06/2024			Varia. 5j.	Varia. 1 janv.
4,82 ^HKD	+3,66%		+1,47%	-30,04%

21/06	La Chine accorde le statut d'examen prioritaire au médicament d'InnoCare contre le lymphome ; les actions bondissent de 6%.	MT
20/06	InnoCare Pharma annonce l'acceptation d'une demande de licence biologique pour le tafasitamab en association avec le lénalidomide pour le traitement du lymphome diffus à grandes cellules B récidivant ou réfractaire chez les patients adultes en Chine	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients	21/06	AQ
InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China	20/06	BU
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress	14/06	BU
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA	11/06	BU
SF Intra-city's revenue surged 25.6% YoY to exceed RMB10 Billion	28/03/23	PR
InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong	28/12/22	AQ
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore	22/11/22	AQ
InnoCare Releases 2022 Third Quarter Results Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales	14/11/22	AQ
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China	21/09/22	AQ
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China	09/09/22	AQ
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA	06/09/22	AQ
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369	24/08/22	AQ
InnoCare Releases 2022 mid-Year Results and Business Highlights	22/08/22	AQ
InnoCare Pharma : INSIDE INFORMATION ANNOUNCEMENT COLLABORATION AND LICENSE AGREEMENT FOR TAFASITAMAB IN GREATER CHINA WITH INCYTE	17/08/21	PU
Biogen : and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis	13/07/21	AQ
InnoCare Pharma : FORM OF PROXY FOR ANNUAL GENERAL MEETING	07/05/21	PU
InnoCare Pharma : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITORS AND NOTICE OF ANNUAL GENERAL MEETING	07/05/21	PU
InnoCare Pharma : ANNOUNCEMENT - CHANGE OF NON-EXECUTIVE DIRECTORS	31/03/21	PU
InnoCare Pharma : Releases 2020 Annual Results and Business Highlights	26/03/21	PR
InnoCare Pharma : INSIDE INFORMATION PROPOSED ISSUE OF RMB SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE	11/03/21	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués InnoCare Pharma Limited

Actions

9969

KYG4783B1032

Communiqués

Filtres